CME photodynamic therapy for choroidal neovascularization: A review

Retina

Volumn 22, Issue 4, 2002, Pages 391-405

  Woodburn, Kathryn W ^a   Engelman, Christopher J ^a   Blumenkranz, Mark S ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

A1PcS4; Age related macular degeneration; ATX S10; Choroidalneovascularization (CNV); Motexafin lutetium (Lu Tex); NPE6; Optrin; Pathologic myopia; Photodynamic therapy (PDT); Purlytin; Tin ethyl etiopurpurin (SnET2); Verteporfin (BPD MA); Visudyne

Indexed keywords

13,17 BISPROPIONYLASPARTIC ACID 3 ETHENYL 7 HYDROXY 8 HYDROXYIMINEETHYLIDENE 2,7,12,18 TETRAMETHYLPORPHINE; ATX S10; BENZOPORPHYRIN DERIVATIVE; ETIOPURPURIN; LUTETIUM TEXAPHYRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PROTOPORPHYRIN; PURLYTIN; TALAPORFIN; TETRASULFOPHTHALOCYANINE CHLOROALUMINUM; TIN ETHYLETIOPURPURIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STRUCTURE; ENDOTHELIUM CELL; ERYTHEMA; HUMAN; HUMAN CELL; MULTICENTER STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SPECTRAL SENSITIVITY; STRUCTURE ANALYSIS; SUBRETINAL NEOVASCULARIZATION; CHEMISTRY; MYOPIA; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION;

CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS; HUMANS; MACULAR DEGENERATION; MYOPIA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 0036672017     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200208000-00001     Document Type: Review

References (68)

1. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a Phase I and II study
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP report 1
3. Clinicopathologic correlation of laser lesion expansion after treatment of choroidal neovascularization
4. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age related macular degeneration. The influence of initial lesion size and visual acuity
5. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials
6. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: A prospective study
7. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization
8. Photodynamic therapy
9. How does photodynamic therapy work?
10. Vascular effects of photodynamic therapy
11. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative
12. A compilation of singlet oxygen yields from biologically relevant molecules
13. Singlet oxygen generation by metallotexaphyrins
14. Photosensitizing potency of structural analogues of benzoporphyrin (BPD) in a mouse model
15. Diels-alder reactions of protoporphyrin IX dimethyl ester with electron-deficient alkynes
16. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer
17. Observations on the synthesis and spectroscopic characteristics of purpurins
18. New photosensitizers for photodynamic therapy: Combined effect of metallopurpurin derivatives and light on transplantable bladder tumors
19. In vitro characterization of mono aspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy
20. Tumor-localizing and photosensitization of photochlorin ATX-S10
21. Photosensitizing efficiency of two regioisomers of the benzoporphyrin derivative monoacid ring A (BPD-MA)
22. The clinical status of benzoporphyrin derivative
23. A Phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic cancer
24. Transperineal photodynamic ablation of the canine prostate
25. Localization and efficacy analysis of the phototherapeutic iutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model
26. Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy
27. Lutetium texaphyrin (lu-tex): A potential new agent for ocular fundus angiography and photodynamic therapy
28. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer
29. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: A Phase I clinical study
30. Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients
31. Photodynamic therapy with phthalocyanine sensitization: Quantitative studies in a transplantable rat fibrosarcoma
32. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents
33. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization
34. Therapeutic effect of interstitial photodynamic therapy using ATX-S10(Na) and a diode laser on radio-resistant SCCVII tumors of C3H/He mice
35. Photodynamic effect of haematoporphyrin on blood microcirculation
36. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light
37. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers
38. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin (BPD)
39. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response
40. Effect of PDT using tin etiopurpurin on tissue microvasculature
41. Assessment of selected damage to tumor vasculature after PDT
42. Use of scanning doppler velocimetry to monitor vascular changes during photodynamic therapy
43. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye
44. Photodynamic therapy of exudative age-related macular degeneration
45. Effects of photodynamic therapy using verteporphyrin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment
46. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey
47. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of retreatments in a phase 1 and 2 study
48. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials - TAP report 2
49. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial - VIP report no. 1
50. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2
51. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2)
52. Photodynamic therapy for corneal neovascularization
53. Visual acuity stabilizes after a single treatment with SnET2-photodynamic therapy in patients with subfoveal choroidal neovascularization
54. Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization
55. Photodynamic therapy of experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin
56. Preliminary results from a phase II dose-response study of photodynamic therapy with motexafin lutetium (Lu-Tex) to treat subfoveal CNV
57. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e-6)
58. Threshold power levels for NP e6 photodynamic therapy
59. Threshold and retreatment parameters of NP e6 photodynamic therapy in retinal and choroidal vessels
60. Problems with and pitfalls of photodynamic therapy
61. Phthalocyanine photodynamic therapy: New strategy for closure of choroidal neovascularization
62. Retinal and choroidal vessel closure using phthalocyanine photodynamic therapy
63. Feasibility of laser targeted photo-occlusion of ocular vessels
64. Selective occlusion of choroidal neovascularization by photodynamic therapy with a water-soluble photosensitizer, ATX-S10
65. Long-term effectiveness of photodynamic therapy using a hydrophilic photosensitizer ATX-S10(Na) against experimental choroidal neovascularization in rats
66. Dynamic observation of selective accumulation of a photosensitizer and its photodynamic effects in rat experimental choroidal neovascularization
67. Selective photodynamic effects of the new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys
68. Properties of melanosomes and their exploitation in the diagnosis and treatment of melanoma